This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Generic Injectable Market

Market Insights on Generic Injectable covering sales outlook, demand forecast & up-to-date key trends

Generic Injectable Market by Product Type (Monoclonal Antibodies, Immunoglobulin, Cytokines, Insulin, Peptide Hormone), Molecule Type (Small Molecule, Large Molecule), Application (Oncology, Infectious Diseases, Diabetes), Route of Administration, End User & Region - Forecast to 2021 - 2031

About the Report

[290 Pages Report] The increasing prevalence of chronic diseases has resulted in investments towards innovations in the field of generic injectables. The demand for immediate treatment options has resulted in the growing popularity of intravenous (IV) or intramascular (IM) routes of drug administration.

For example, IM administration of insulin provides better patient outcomes. Generic injectable products offer a number of advantages such as faster approvals, improved availability of biologic drugs in development pipelines, and a higher preference for injectable drug delivery.

Factors such as cost-effectiveness, and better patient outcomes are bolstering sales prospects for products including vaccines, monoclonal antibodies, peptides, immunoglobulins, and antibodies.

Generic injectables are also increasingly recognized as cost-effective treatments as compared with branded alternatives. These factors are driving up adoption rates in the generic injectable market.

In its latest study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for generic injectables. The report tracks global sales in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the generic injectable market.

Customize this Report

Let us know your requirement to get
100% FREE customization

How Does the Historical and Future Outlook of Generic Injectables Compare?

The wide prevalence of lifestyle-based ailments such as diabetes in developed and developing countries is increasing driven by a number of factors including family medical history, obesity and others. Increasing prevalence of diabetes adds up to medical costs for management of the condition.

As per data from the World Health Organization (WHO), the prevalence of diabetes is expected to surge from 117 million in 2000 to 422.0 million in 2030 with a rapid rise in patient numbers. The prevalence of diabetes across all age-groups was estimated to be 2.8% in 2000, which is projected to rise to and 4.4% in 2030.

Previously, due to insufficient clinical data and safety concerns about generic injectables, uses were limited in the treatment of chronic ailments. According to Future Market Insights, generic injectable sales have grown at an 8.8% CAGR between 2016 and 2020.

The COVID-19 pandemic has changed priorities in national healthcare processes and spending, but this is considered to be a short-term negative impact on the generic injectable market. Future Market Insights expects the global generic injectable market to rise at 11.6 % CAGR through the end of the forecast period in 2031.

How are Branded Versions Contributing to Sales of Generic Injectables?

The expiry of patents of branded items and reduced numbers of new launches have positively influenced generic medications and have contributed to the development of Generic Injectable Market players and product sales.

Generic injectable costs are relatively low when compared with the costs of branded products providing significant impetus to market growth while also expanding net sales. Generic drugs are resulting in losses for pharmaceutical companies with support from government incentives for participants in the market.

Across economies, there has been a rising trend in healthcare expenditure in the last decade. Factors responsible include inflation rates that contribute significantly towards drug price spirals. Utilization of capacities and rates have remained stagnant since 2000 and it’s only prices that are driving growth. In this regard, close focus on both pricing and healthcare access are key aspects that need to be considered while containing medical costs.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why are Pipeline Drug Approvals and Sterile Injectables Gaining Importance?

Medications in the drug development pipelines with parenteral applications has risen from 56% to 58%, between 2020 and 2021. This can be attributed to the scaling of biologics. Expansion of generic injectable in pipeline result in the expansion and R&D efforts involved in the conventional injectable market.

Generic injectables affirmed as new molecule entities (NMEs) by the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) estimated a peak of 57% in 2020 and has since dropped to 40% in recent months.

Research into new treatment and route of administration options for chronic diseases has risen. Expansion will drive development in the generic injectable market.

Major drug production organizations have reported their expectations to invest in manufacturing facilities with the objective of improving manufacturing limits, cutting down corporate expense rates, and building their international presence in emerging economies like India and China, where manufacturing cost is relatively lower as compared to Europe and North America.

The new duty changes in the U.S., have resulted in lower corporate tax rates, and have boosted biopharmaceutical organizations to bolster production capacities. In July 2020, Pfizer reported an arrangement to contribute around US$ 465 million to fabricate a sterile injectable plant in Portage, Michigan.

This development is a part of the company’s plan to invest around US$ 5 billion for every U.S.- based capital task in line with corporate assessment changes in the country.

High Operational Costs Restraining Generic injectable Growth?

Generic injectables need complex equipment for manufacturing, all of which require appropriate certification and sterilization standards for each batch prior to production. This leads to high operating costs and high debt levels, due to purchase/ rent-to-lease of capital equipment.

Additionally, regulatory cost burdens are significantly higher owing to FDA mandates of maintaining high degrees of care not only in the manufacturing process, but also for packaging, storage and distribution.

Some areas contributing to high level of expenditure include sterility from bacterial and fungal contamination, stability issues, separation of extractable and leachable substances from packaging materials along with transportation and logistics.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

What Are the Opportunities Involved in Generic injectables?

Manufacturing of sterile products has been increasingly outsourced to CMOs and CDMOs. This has resulted in major monetary savings among the larger drug producers. The development is witnessing increased traction in the oncology segment. Further, the expansion of large molecule products into injectables are fueling developments.

Information geneted from bioavailability studies demonstrating a connection among pharmacodynamics and pharmacokinetics for such generic injectables is bolstering market prospects. India's power of favored assembly areas for major drug production units is gradually expanding to different areas including research and clinical practices, owing to India's low operational costs and significant expertise in the field.

According to the Pharma India 2021 report, India overwhelms the generic medications market; it traded US$17.3 billion worth of medications - approximately 20% of the worldwide market - in 2017-18. This trend is unlikely to change in the near future.

In 2017, the FDA affirmed 80 new vagrant signs, with 53 endorsed in 2020. In this way vagrant medication classification will give critical development freedom to producers of nonexclusive injectable products.

Country-wise Insights

How Lucrative is the Opportunity in the China?

China is one of the leading producers of pharmaceutical products in the world. However, China is experiencing dramatic increase in wages and is consequently getting more expensive for contract manufacturing processes. Despite this, Asia remains a very affordable region for manufacturing.

Also, the government and regulatory authorities in China are implementing several cost-containment plans to ease the burden on the healthcare sector. The Chinese government is actively taking initiatives to encourage various research activities for the development and treatment plan for generic injectables for cancer.

The World Health Organization reported that in 2018 the incidence rate of “westernized lifestyle-related Diseases” such as diabetes, hypertension, together with obesity and hormonal imbalance has been found to be a major cause of chronic diseases showing an upward trend in China.

Furthermore, the higher prevalence of chronic diseases in the China, with a number of service providers are conducting campaigns to raise general awareness among people related to these diseases. This is likely to support the overall market growth in the country.

What Developments Drive Success in the U.K.?

Frequent  tech advancements, the demand for wider product portfolios, and improvements to drug development pipelines and production capacities of existing injectable players are key factors speeding up the promising growth in the UK of the generic injectable market. New acquisitions have been driven by the need to widen the portfolio for nonexclusive clean injectables in the UK market.

For Instance, in January 2021 – Samsung Biologics announced another successful Investigational New Drug (IND) clearance from the FDA for cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market.

What are the Factors Restricting Generic Injectables in Germany?

Regulatory guidelines are relatively strict in Germany. As a result, achieving approvals for drug development and production is harder. Authorities responsible for the registration of pharmaceuticals is an independent higher federal authority under the Federal Ministry of Health.

The institute aims to continuously improve the safety of drugs and monitor the risks associated with medical devices and narcotics. BfArM’s headquarters are located in Bonn and Berlin.

BfArM is the authority responsible for licensing medicinal products for humans. Sera, vaccines, allergens, test sera, test antigens, and blood products are licensed by the Paul-Ehrlich-Institute. Marketing authorizations for medicinal products for use in animals are granted by the Federal Office of Consumer Protection and Food Safety. Complying with the difference in standards will play key roles in the future of the industry.

Generic Injectable Market Download Report Brochure

How is R&D Expenditure Affecting the U.S Market?

The healthcare R&D expenditure in the U.S. rose by over 33% from 2018 to 2020. Numerous investors in the United States are spending on R&D pertaining to the healthcare industry, federal government, universities, and foundations.

Rapid growth of healthcare expenditure is resulting in new molecule discovery, and the evaluation of various molecules for potential treatments. The U.S. witnessed approximately 400 injectable in pipeline during 2020. Large molecules are a key focus of the pharmaceutical industry at present. This is due to the highly biocompatible nature of large molecules.

The approval of large molecules and biosimilars is a lengthy process that requires a significantly high investment for research. Increase in R&D spending in the pharmaceutical industry offers the opportunity for numerous large molecules to enter the pipeline.

Oncology remains the key focus of research owing to a large patient pool that offers significant growth opportunities once launched in the market. Most products are in phase 3 of the pipeline. This is because many manufacturers strategize to gain approvals for pre-marketed products for new indications in order to expand their customer base.

What is Supporting Surging Adoption Of Generic Injectables in India?

Growth of government spending in pharmaceutical sectors is a major factor generating penetration opportunities in india. High levels of capital investment as continuous support to keep up with USFDA cGMP generic clean injectable plants will positively influence market developments.

The lapse of patents for branded items and reduced number of new item launches have brought about the increase in generic injectable deals in India. Relatively relaxed standards of regulatory approval of generic injectables have contributed to higher investments in production to ensure higher quality levels.

The usual time span for regulatory approvel for sterile medications in the countyr are more than three to four years. A large gap between demand and supply adds to deficiencies, create value building incentives. Practical medication for working class populace will also contribute to the market.

Category-wise Insights

Why is Intravenous Administration Driving Revenues?

Intravenous injections are though to be more effective for a number of life treating diseases and associated treatments. Ease of operations by doctors and lower costs, drive physicians to choose intravenous options. Lower costs for patients also results in higher revenue generation in the generic injectable services market with increased sales.

What’s the Market Share of Monoclonal Antibodies by product type?

The monoclonal antibodies segment will continue to dominate the market during the forecast period. According to FMI, the segment is expected to hold around 44% of the market share, in terms of service providers, through the end of 2031. Hospitals are equipped with advanced injectable for fast recovery of patients, through immunity boosting offerings which is finding roles to treat patients with various chronic diseases.

Why Large Molecule Type have good share ?

Most of the pharmaceutical generic companies are focusing on research of large molecule delivery by injectable route that create good opportunities in this area. And in forcast period as well this segment is showing largest share of 57%.

Why Hospital Pharmacies give largest sale through out forcast period  ?

Injection are something which cant be self administrated so to take it heatlcare docters are required so for that purpose we need to go to hospitals to take injection. Big hospitals have their own pharmacies so all the medicine required in hospital comes from their pharmacies incuding injection  so that it give large sale. It give around 94 Bn sales in forcast period.

How has Diabetes Contributed to Sales of Generic Injectable?

Diabetes currently leads the market in terms of indication. The increasing prevalence of diabetes around the world will continue to drive demand. The prevalence of diabetes in developed as well as developing countries is increasing due to factors such family history of diabetes and obesity among others. Increasing prevalence of diabetes adds up to the cost of management of diabetes.

As per the World Health Organization (WHO), the prevalence of diabetes has surged from 117 million in 2000 to 422.0 million in 2030 and the number is rising rapidly. The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030.

The prevalence of diabetes is higher in men than women, but there are more women with diabetes than men. Urban population in developing countries is projected to double between 2000 and 2030.

The prevalence rate is high particularly in developing countries as compared to developed countries. With the incidence set to rise, the demand for effective is forecast to surge with CAGR of 12%. This will in turn fuel the demand for Generic Injectable in the coming years.

Competitive Landscape

Manufacturers in the generic injectables market are aiming to carry out strategic collaborations and R&D.

For instance, In January 2020, Merck announced its Strategic Collaboration for oncology platform with Taiho Pharmaceutical Co, Ltd. And Taiho Pharmaceutical Co, Ltd to expand its focus on small molecule in injection inhibitors for cancer research.

For Instance, In January 2019, Sanofi S.A acquired Biogen Spin-Off in $11.6-Billion Deal.

In March 2021, Pfizer Inc. and Eli Lilly and Company announced the approval U.S. FDA for tanezumab for osteoartities Pain taken subcutaneously (SC)

The company is strategically making promotional plans for its established prescription brands to increase their awareness within the prescription market Its ‘Get Old’ campaign also makes a frequent appearance on the main company feeds and through its own Twitter and Facebook page.

Sanofi AG may be known for blockbuster injectable drug products such as Libtayo and Sarcalisa, but the company is engaged in effective promotions to increase its brand recall among established prescription brands.                         

Some of the leading companies operating in the market are:

  • Samsung Biologics Co Ltd  
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • Cipla Ltd
  • Pfizer Inc
  • Fresenius Kabi
  • Sanofi S.A
  • AstraZeneca Plc
  • Teva Pharmaceuticals.
  • Mylan N.A
  • Baxter International
  • Dr. Reddy’s Laboratories Ltd

Scope of the Report

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

USD billion for Value

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa

Key Segments Covered

Product, Molecule, Application, Route of Administration, Distribution Channel and Region

Key Companies Profiled

  • Samsung Biologics Co Ltd
  • Aurobindo Pharma Limited 
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • Cipla Ltd
  • Pfizer Inc
  • Fresenius Kabi
  • Sanofi S.A
  • AstraZeneca Plc
  • Teva Pharmaceuticals.
  • Mylan N.A
  • Baxter International
  • Dr. Reddy’s Laboratories Ltd

Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Generic injectable Market by Category

Product type:

  • Monoclonal Antibodies Generic injectable
  • Immunoglobulin Generic injectable
  • Cytokines Generic injectable
  • Insulin Generic injectable
  • Peptide Hormones Generic injectable
  • Blood Factors Generic injectable
  • Peptide Antibiotics Generic injectable
  • Vaccines Generic injectable
  • Small Molecule Antibiotics Generic injectable
  • Chemotherapy Agents Generic injectable

Molecule Type:

  • Small Molecule Generic injectable
  • Large Molecule Generic injectable

Application:

  • Oncology Generic injectable
  • Infectious Diseases Generic injectable
  • Diabetes Generic injectable
  • Blood Disorders Generic injectable
  • Hormonal Disorders Generic injectable
  • Musculoskeletal Disorders Generic injectable
  • CNS Diseases Generic injectable
  • Pain Management Generic injectable
  • Cardiovascular Diseases Generic injectable

Route of Administration:

  • Intravenous (IV) Generic injectable
  • Intramuscular (IM) Generic injectable
  • Subcutaneous (SC) Generic injectable

Distribution channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

The US currently leads the global market for generic injectable. Sales in the US will be over 95% of the total global demand throughout the forecast period.

Monoclonal Antibodies is dominating the segment in terms of product. Due to its fast action and cost effective and will continue increasing through the forecast period.

Infectious disease is having more Patient worldwide. There is more prevalence of bacterial or viral infection that is main reason for the lubrication of this segment.

Intravenous is showing consistence growth in market due it instant effect on route cause and relief in indication also site action is more seen.

Hospitals are leading the service provider segment of the generic injectable services market, owing to their advanced medical facilities and higher footfall of patients.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Key Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting The Market

    3.2. Recent Development Trends 

    3.3. Key Industrial Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Key Disease Epidemiology

    4.3. Pipeline (Clinical Developments) Assessment 

    4.4. Key Industry Trends 

    4.5. Regulatory Landscape

    4.6. Promotional Strategies by Key Players

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure Outlook

        5.1.3. Growth of Healthcare Sector in Emerging Nations

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Historic Growth of Top Players 

        5.2.2. Product Adoption & Availability

        5.2.3. Technology Advancement & IP Rights 

        5.2.4. New Product Approval

        5.2.5. Regulatory Framework

        5.2.6. Reimberment Scenario 

        5.2.7. Product Pricing

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID19 Crisis Impact Analysis

    6.1. Current COVID19 Statistics and Probable Future Impact

    6.2. Current GDP Projection and Probable Impact

    6.3. Current Economic Projection as compared to 2008 Economic analysis

    6.4. COVID19 and Impact Analysis

        6.4.1. By Product Type

        6.4.2. By Molecule Type

        6.4.3. By Application 

        6.4.4. By Route of Administration

        6.4.5. By Distribution Channel

        6.4.6. By Region

    6.5. 2021 Market Scenario

    6.6. Quarter by Quarter Forecast

    6.7. Projected Recovery Quarter

    6.8. Recovery Scenario – Short term, Midterm and Long Term Impact

7. Generic Injectable Market Demand (in Value or Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021–2031

    7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031, by Product Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2016 - 2020

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2021 - 2031

        8.3.1. Monoclonal Antibodies

        8.3.2. Immunoglobulin

        8.3.3. Cytokines

        8.3.4. Insulin

        8.3.5. Peptide Hormones

        8.3.6. Blood Factors

        8.3.7. Peptide Antibiotics

        8.3.8. Vaccines

        8.3.9. Small Molecule Antibiotics

        8.3.10. Chemotherapy Agents

        8.3.11. Others 

    8.4. Market Attractiveness Analysis By Product Type 

9. Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031, by Molecule Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Molecule Type, 2016 - 2020

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Molecule Type, 2021 - 2031

        9.3.1. Small Molecule

        9.3.2. Large Molecule 

    9.4. Market Attractiveness Analysis By Molecule Type 

10. Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031, By Application

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Application, 2016 - 2020

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2021 - 2031

        10.3.1. Oncology

        10.3.2. Infectious Diseases

        10.3.3. Diabetes

        10.3.4. Blood Disorders

        10.3.5. Hormonal Disorders

        10.3.6. Musculoskeletal Disorders

        10.3.7. CNS Diseases

        10.3.8. Pain Management

        10.3.9. Cardiovascular Diseases

    10.4. Market Attractiveness Analysis By Application

11. Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2016 - 2020

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2021 - 2031

        11.3.1. Intravenous (IV)

        11.3.2. Intramuscular (IM)

        11.3.3. Subcutaneous (SC) 

    11.4. Market Attractiveness Analysis By Route of Administration

12. Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016 - 2020

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021 - 2031

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Drug Stores

        12.3.4. Online Pharmacies

    12.4. Market Attractiveness Analysis By Distribution Channel

13. Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031, by Region

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016 - 2020

    13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2031

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. East Asia

        13.3.5. South Asia

        13.3.6. Oceania

        13.3.7. Middle East and Africa (MEA)

    13.4. Market Attractiveness Analysis By Region

14. North America Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        14.3.1. By Country

            14.3.1.1. U.S.

            14.3.1.2. Canada

        14.3.2. By Product Type 

        14.3.3. By Molecule Type

        14.3.4. By Application

        14.3.5. By Route of Administration

        14.3.6. By Distribution Channel

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. Latin America Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        15.3.1. By Country

            15.3.1.1. Brazil

            15.3.1.2. Mexico

            15.3.1.3. Argentina

            15.3.1.4. Rest of Latin America

        15.3.2. By Product Type

        15.3.3. By Molecule Type

        15.3.4. By Application

        15.3.5. By Route of Administration

        15.3.6. By Distribution Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Europe Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        16.3.1. By Country

            16.3.1.1. Germany

            16.3.1.2. Italy

            16.3.1.3. France

            16.3.1.4. U.K.

            16.3.1.5. Spain

            16.3.1.6. BENELUX

            16.3.1.7. Russia

            16.3.1.8. Rest of Europe

        16.3.2. By Product Type 

        16.3.3. By Molecule Type

        16.3.4. By Application

        16.3.5. By Route of Administration

        16.3.6. By Distribution Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. South Asia Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        17.3.1. By Country

            17.3.1.1. India

            17.3.1.2. Thailand

            17.3.1.3. Malaysia

            17.3.1.4. Rest of South Asia

        17.3.2. By Product Type 

        17.3.3. By Molecule Type

        17.3.4. By Application

        17.3.5. By Route of Administration

        17.3.6. By Distribution Channel

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. East Asia Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        18.3.1. By Country

            18.3.1.1. China

            18.3.1.2. Japan

            18.3.1.3. South Korea

        18.3.2. By Product Type

        18.3.3. By Molecule Type

        18.3.4. By Application

        18.3.5. By Route of Administration

        18.3.6. By Distribution Channel

    18.4. Market Attractiveness Analysis

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. Oceania Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        19.3.1. By Country

            19.3.1.1. Australia

            19.3.1.2. New Zealand

        19.3.2. By Product Type 

        19.3.3. By Molecule Type

        19.3.4. By Application

        19.3.5. By Route of Administration

        19.3.6. By Distribution Channel

    19.4. Market Attractiveness Analysis

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2020

    20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021 - 2031

        20.3.1. By Country

            20.3.1.1. GCC Countries

            20.3.1.2. South Africa

            20.3.1.3. Rest of Middle East and Africa

        20.3.2. By Product Type 

        20.3.3. By Molecule Type

        20.3.4. By Application

        20.3.5. By Route of Administration

        20.3.6. By Distribution Channel

    20.4. Market Attractiveness Analysis

    20.5. Key Market Participants - Intensity Mapping

    20.6. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Generic Injectable Market Analysis 2016-2020 and Forecast 2021-2031

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. Generic Injectable Market Analysis

        21.2.1. By Product Type

        21.2.2. By Molecule Type

        21.2.3. By Application

        21.2.4. By Route of Administration

        21.2.5. By Distribution Channel

    21.3. Canada Generic Injectable Market Analysis

        21.3.1. By Product Type

        21.3.2. By Molecule Type

        21.3.3. By Application

        21.3.4. By Route of Administration

        21.3.5. By Distribution Channel

    21.4. Mexico Generic Injectable Market Analysis

        21.4.1. By Product Type

        21.4.2. By Molecule Type

        21.4.3. By Application

        21.4.4. By Route of Administration

        21.4.5. By Distribution Channel

    21.5. Brazil Generic Injectable Market Analysis

        21.5.1. By Product Type

        21.5.2. By Molecule Type

        21.5.3. By Application

        21.5.4. By Route of Administration

        21.5.5. By Distribution Channel

    21.6. Argentina Generic Injectable Market Analysis

        21.6.1. By Product Type 

        21.6.2. By Molecule Type

        21.6.3. By Application

        21.6.4. By Route of Administration

        21.6.5. By Distribution Channel

    21.7. Germany Generic Injectable Market Analysis

        21.7.1. By Product Type 

        21.7.2. By Molecule Type

        21.7.3. By Application

        21.7.4. By Route of Administration

        21.7.5. By Distribution Channel

    21.8. Italy Generic Injectable Market Analysis

        21.8.1. By Product Type 

        21.8.2. By Molecule Type

        21.8.3. By Application

        21.8.4. By Route of Administration

        21.8.5. By Distribution Channel

    21.9. France Generic Injectable Market Analysis

        21.9.1. By Product Type 

        21.9.2. By Molecule Type

        21.9.3. By Application

        21.9.4. By Route of Administration

        21.9.5. By Distribution Channel

    21.10. U.K. Generic Injectable Market Analysis

        21.10.1. By Product Type 

        21.10.2. By Molecule Type

        21.10.3. By Application

        21.10.4. By Route of Administration

        21.10.5. By Distribution Channel

    21.11. Spain Generic Injectable Market Analysis

        21.11.1. By Product Type 

        21.11.2. By Molecule Type

        21.11.3. By Application

        21.11.4. By Route of Administration

        21.11.5. By Distribution Channel

    21.12. BENELUX Generic Injectable Market Analysis

        21.12.1. By Product Type 

        21.12.2. By Molecule Type

        21.12.3. By Application

        21.12.4. By Route of Administration

        21.12.5. By Distribution Channel

    21.13. Russia Generic Injectable Market Analysis

        21.13.1. By Product Type 

        21.13.2. By Molecule Type

        21.13.3. By Application

        21.13.4. By Route of Administration

        21.13.5. By Distribution Channel

    21.14. China Generic Injectable Market Analysis

        21.14.1. By Product Type 

        21.14.2. By Molecule Type

        21.14.3. By Application

        21.14.4. By Route of Administration

        21.14.5. B Distribution Channel

    21.15. Japan Generic Injectable Market Analysis

        21.15.1. By Product Type 

        21.15.2. By Molecule Type

        21.15.3. By Application

        21.15.4. By Route of Administration

        21.15.5. By Distribution Channel

    21.16. South Korea Generic Injectable Market Analysis

        21.16.1. By Product Type 

        21.16.2. By Molecule Type

        21.16.3. By Application

        21.16.4. By Route of Administration

        21.16.5. By Distribution Channel

    21.17. India Generic Injectable Market Analysis

        21.17.1. By Product Type 

        21.17.2. By Molecule Type

        21.17.3. By Application

        21.17.4. By Route of Administration

        21.17.5. By Distribution Channel

    21.18. Thailand Generic Injectable Market Analysis

        21.18.1. By Product Type 

        21.18.2. By Molecule Type

        21.18.3. By Application

        21.18.4. By Route of Administration

        21.18.5. By Distribution Channel

    21.19. Malaysia Generic Injectable Market Analysis

        21.19.1. By Product Type 

        21.19.2. By Molecule Type

        21.19.3. By Application

        21.19.4. By Route of Administration

        21.19.5. By Distribution Channel

    21.20. Australia Generic Injectable Market Analysis

        21.20.1. By Product Type 

        21.20.2. By Molecule Type

        21.20.3. By Application

        21.20.4. By Route of Administration

        21.20.5. By Distribution Channel

    21.21. New Zealand Generic Injectable Market Analysis

        21.21.1. By Product Type 

        21.21.2. By Molecule Type

        21.21.3. By Application

        21.21.4. By Route of Administration

        21.21.5. By Distribution Channel

    21.22. GCC Countries Generic Injectable Market Analysis

        21.22.1. By Product Type 

        21.22.2. By Molecule Type

        21.22.3. By Application

        21.22.4. By Route of Administration

        21.22.5. By Distribution Channel

    21.23. Turkey Generic Injectable Market Analysis

        21.23.1. By Product Type 

        21.23.2. By Molecule Type

        21.23.3. By Application

        21.23.4. By Route of Administration

        21.23.5. By Distribution Channel

    21.24. South Africa Generic Injectable Market Analysis

        21.24.1. By Product Type 

        21.24.2. By Molecule Type

        21.24.3. By Usage

        21.24.4. By Route of Administration

        21.24.5. By Distribution Channel

22. Market Structure Analysis

    22.1. Market Analysis by Tier of Companies 

    22.2. Market Share Analysis of Top Players

    22.3. Market Concentration

    22.4. Market Presence Analysis

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Benchmarking

    23.3. Competition Deep pe (Tentative List)

        23.3.1. Sanofi S.A

            23.3.1.1. Overview

            23.3.1.2. Product Portfolio

            23.3.1.3. Key Financials 

            23.3.1.4. Sales Footprint

            23.3.1.5. Strategy Overview

                23.3.1.5.1. Marketing Strategy

                23.3.1.5.2. Product Strategy

                23.3.1.5.3. Channel Strategy

        23.3.2. Samsung Biologics Co Ltd

            23.3.2.1. Overview

            23.3.2.2. Product Portfolio

            23.3.2.3. Key Financials 

            23.3.2.4. Sales Footprint

            23.3.2.5. Strategy Overview

                23.3.2.5.1. Marketing Strategy

                23.3.2.5.2. Product Strategy

                23.3.2.5.3. Channel Strategy

        23.3.3. Aurobindo Pharma Limited  

            23.3.3.1. Overview

            23.3.3.2. Product Portfolio

            23.3.3.3. Key Financials 

            23.3.3.4. Sales Footprint

            23.3.3.5. Strategy Overview

                23.3.3.5.1. Marketing Strategy

                23.3.3.5.2. Product Strategy

                23.3.3.5.3. Channel Strategy

        23.3.4. Sun Pharmaceutical Industries Ltd. 

            23.3.4.1. Overview

            23.3.4.2. Product Portfolio

            23.3.4.3. Key Financials 

            23.3.4.4. Sales Footprint

            23.3.4.5. Strategy Overview

                23.3.4.5.1. Marketing Strategy

                23.3.4.5.2. Product Strategy

                23.3.4.5.3. Channel Strategy

        23.3.5. Novartis AG

            23.3.5.1. Overview

            23.3.5.2. Product Portfolio

            23.3.5.3. Key Financials 

            23.3.5.4. Sales Footprint

            23.3.5.5. Strategy Overview

                23.3.5.5.1. Marketing Strategy

                23.3.5.5.2. Product Strategy

                23.3.5.5.3. Channel Strategy

        23.3.6. Merck & Co. Inc

            23.3.6.1. Overview

            23.3.6.2. Product Portfolio

            23.3.6.3. Key Financials 

            23.3.6.4. Sales Footprint

            23.3.6.5. Strategy Overview

                23.3.6.5.1. Marketing Strategy

                23.3.6.5.2. Product Strategy

                23.3.6.5.3. Channel Strategy

        23.3.7. Cipla Ltd 

            23.3.7.1. Overview

            23.3.7.2. Product Portfolio

            23.3.7.3. Key Financials 

            23.3.7.4. Sales Footprint

            23.3.7.5. Strategy Overview

                23.3.7.5.1. Marketing Strategy

                23.3.7.5.2. Product Strategy

                23.3.7.5.3. Channel Strategy

        23.3.8. Pfizer Inc

            23.3.8.1. Overview

            23.3.8.2. Product Portfolio

            23.3.8.3. Key Financials 

            23.3.8.4. Sales Footprint

            23.3.8.5. Strategy Overview

                23.3.8.5.1. Marketing Strategy

                23.3.8.5.2. Product Strategy

                23.3.8.5.3. Channel Strategy

        23.3.9. Fresenius Kab

            23.3.9.1. Overview

            23.3.9.2. Product Portfolio

            23.3.9.3. Key Financials 

            23.3.9.4. Sales Footprint

            23.3.9.5. Strategy Overview

                23.3.9.5.1. Marketing Strategy

                23.3.9.5.2. Product Strategy

                23.3.9.5.3. Channel Strategy

        23.3.10. AstraZeneca Plc

            23.3.10.1. Overview

            23.3.10.2. Product Portfolio

            23.3.10.3. Key Financials 

            23.3.10.4. Sales Footprint

            23.3.10.5. Strategy Overview

                23.3.10.5.1. Marketing Strategy

                23.3.10.5.2. Product Strategy

                23.3.10.5.3. Channel Strategy

        23.3.11. Teva Pharmaceuticals.

            23.3.11.1. Overview

            23.3.11.2. Product Portfolio

            23.3.11.3. Key Financials 

            23.3.11.4. Sales Footprint

            23.3.11.5. Strategy Overview

                23.3.11.5.1. Marketing Strategy

                23.3.11.5.2. Product Strategy

                23.3.11.5.3. Channel Strategy

        23.3.12. Mylan N.

            23.3.12.1. Overview

            23.3.12.2. Product Portfolio

            23.3.12.3. Key Financials 

            23.3.12.4. Sales Footprint

            23.3.12.5. Strategy Overview

                23.3.12.5.1. Marketing Strategy

                23.3.12.5.2. Product Strategy

                23.3.12.5.3. Channel Strategy

        23.3.13. Baxter International

            23.3.13.1. Overview

            23.3.13.2. Product Portfolio

            23.3.13.3. Key Financials 

            23.3.13.4. Sales Footprint

            23.3.13.5. Strategy Overview

                23.3.13.5.1. Marketing Strategy

                23.3.13.5.2. Product Strategy

                23.3.13.5.3. Channel Strategy

        23.3.14. Dr. Reddy’s Laboratories Ltd

            23.3.14.1. Overview

            23.3.14.2. Product Portfolio

            23.3.14.3. Key Financials 

            23.3.14.4. Sales Footprint

            23.3.14.5. Strategy Overview

                23.3.14.5.1. Marketing Strategy

                23.3.14.5.2. Product Strategy

                23.3.14.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Expenditure on Health (% of GDP) by Country, 2016-2021

Table 02: Expenditure on Health (% of GDP) by Country, 2016-2021

Table 03: Global Generic Injectable Market Size Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031, By Product Type

Table 04: Global Generic Injectable Market Size Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031 , By Molecule Type

Table 05: Global Generic Injectable Market Size Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031 , By Application

Table 06: Global Generic Injectable Market Size Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031 , By Route of Administration

Table 07: Global Generic Injectable Market Size Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031 , By Distribution Channel

Table 08: Global Generic Injectable Market Size Value (US$ Bn) Analysis 2016–2020 and Forecast 2021–2031 , By Region

Table 09: North America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Country

Table 10: North America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Product Type

Table 11: North America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 ,By Molecule Type

Table 12: North America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Application

Table 13: North America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Route of Administration

Table 14: North America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Distribution Channel

Table 15: Latin America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Country

Table 16: Latin America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Product Type

Table 17: Latin America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Molecule Type

Table 18: Latin America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Application

Table 19: Latin America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Route of Administration

Table 20: Latin America Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Distribution Channel

Table 21: Europe Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Country

Table 22: Europe Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Product Type

Table 23: Europe Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Molecule Type

Table 24: Europe Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Application

Table 25: Europe Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Route of Administration

Table 26: Europe Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031, By Distribution Channel

Table 27: South Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Country

Table 28: South Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Product Type

Table 29: South Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031, By Molecule Type

Table 30: South Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031, By Application

Table 31: South Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031, By Route of Administration

Table 32: South Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031, By Distribution Channel

Table 33: East Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Country

Table 34: East Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Product Type

Table 35: East Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Molecule Type

Table 36: East Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Application

Table 37: East Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Route of Administration

Table 38: East Asia Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Distribution Channel

Table 39: Oceania Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Country

Table 40: Oceania Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Product Type

Table 41: Oceania Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Molecule Type

Table 42: Oceania Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Application

Table 43: Oceania Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Route of Administration

Table 44: Oceania Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Distribution Channel

Table 45: MEA Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Country

Table 46: MEA Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Product Type

Table 47: MEA Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Molecule Type

Table 48: MEA Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Application

Table 49: MEA Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Route of Administration

Table 50: MEA Generic Injectable Market size (US$ Bn)Analysis-2016–2020 and Forecast 2021-2031 , By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Generic Injectable Market Value Share, By Product (2020)

Figure 02: Global Generic Injectable Market Value Share, By Molecule (2020)

Figure 03: Global Generic Injectable Market Value Share, By Application  (2020)

Figure 04: Global Generic Injectable Market Value Share, By Route of Administration  (2020)

Figure 05: Global Generic Injectable Market Value Share, By Distribution Channel (2020)

Figure 06: Pipeline Products Share (%), by Therapeutic Area (2020)

Figure 07: Pipeline Products Share (%), by Phase (2020)

Figure 08: Pipeline Products Share (%), by Molecule Type (2020)

Figure 09: Global Generic Injectable Market Value Analysis (US$ Bn), 2016-2020

Figure 10: Global Generic Injectable Market Value Analysis (US$ Bn), 2021–2031

Figure 11: Global Generic Injectable Market Absolute $ Opportunity, 2021-2031

Figure 12: Global Generic Injectable Market Analysis by Product Type –2021 & 2031

Figure 13: Global Generic Injectable Market Y-o-Y Growth Projections by Product Type, 2021-2031

Figure 14: Global Generic Injectable Market Attractiveness Analysis By Product Type, 2021–2031 

Figure 15: Global Generic Injectable Market Share Analysis (%) By Molecule Type, 2021 & 2031

Figure 16: Global Generic Injectable Market Y-o-Y Growth (%) By Molecule Type, 2021–2031

Figure 17: Global Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021–2031 

Figure 18: Global Generic Injectable Market Share Analysis (%) By Application, 2021 & 2031

Figure 19: Global Generic Injectable Market Y-o-Y Growth (%) By Application, 2021–2031

Figure 20: Global Generic Injectable Market Attractiveness Analysis By Application, 2021–2031 

Figure 21: Global Generic Injectable Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 22: Global Generic Injectable Market Y-o-Y Growth (%) By Route of Administration, 2021–2031

Figure 23: Global Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021–2031 

Figure 24: Global Generic Injectable Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 25: Global Generic Injectable Market Y-o-Y Growth (%) By Distribution Channel, 2021–2031

Figure 26: Global Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021–2031 

Figure 27: Global Generic Injectable Market Share Analysis (%) By Region, 2021 & 2031

Figure 28: Global Generic Injectable Market Y-o-Y Growth (%) By Region, 2021–2031

Figure 29: Global Generic Injectable Market Attractiveness Analysis By Region, 2021–2031 

Figure 30: North America Generic Injectable Market Size Analysis, 2016–2020

Figure 31: North America Generic Injectable Market Forecast & Y-o-Y growth, 2021–2031

Figure 32: North America Generic Injectable Market Attractiveness Analysis By Country, 2021-2031

Figure 33: North America Generic Injectable Market Attractiveness Analysis By Product Type, 2021-2031

Figure 34: North America Generic Injectable Market Attractiveness Analysis By Application, 2021-2031

Figure 35: North America Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021-2031

Figure 36: North America Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021-2031

Figure 37: North America Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021-2031

Figure 38: Latin America Generic Injectable Market Size Analysis, 2016–2020

Figure 39: Latin America Generic Injectable Market Forecast & Y-o-Y growth, 2021–2031

Figure 40: Latin America Generic Injectable Market Attractiveness Analysis By Country, 2021-2031

Figure 41: Latin America Generic Injectable Market Attractiveness Analysis By Product Type, 2021-2031

Figure 42: Latin America Generic Injectable Market Attractiveness Analysis By Application, 2021-2031

Figure 43: Latin America Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021-2031

Figure 44: Latin America Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021-2031

Figure 45: Latin America Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021-2031

Figure 46: Europe Generic Injectable Market Size Analysis, 2016–2020

Figure 47: Europe Generic Injectable Market Forecast & Y-o-Y growth, 2021–2031

Figure 48: Europe Generic Injectable Market Attractiveness Analysis By Country, 2021-2031

Figure 49: Europe Generic Injectable Market Attractiveness Analysis By Product Type, 2021-2031

Figure 50: Europe Generic Injectable Market Attractiveness Analysis By Application, 2021-2031

Figure 51: Europe Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021-2031

Figure 52: Europe Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021-2031

Figure 53: Europe Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021-2031

Figure 54: South Asia Generic Injectable Market Size Analysis, 2016–2020

Figure 55: South Asia Generic Injectable Market Forecast & Y-o-Y growth 2021–2031

Figure 56: South Asia Generic Injectable Market Attractiveness Analysis By Country, 2021-2031

Figure 57: South Asia Generic Injectable Market Attractiveness Analysis By Product Type, 2021-2031

Figure 58: South Asia Generic Injectable Market Attractiveness Analysis By Application, 2021-2031

Figure 59: South Asia Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021-2031

Figure 60: South Asia Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021-2031

Figure 61: South Asia Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021-2031

Figure 62: East Asia Generic Injectable Market Size Analysis, 2016–2020

Figure 63: East Asia Generic Injectable Market Forecast & Y-o-Y growth, 2021–2031

Figure 64: East Asia Generic Injectable Market Attractiveness Analysis By Country, 2021-2031

Figure 65: East Asia Generic Injectable Market Attractiveness Analysis By Product Type, 2021-2031

Figure 66: East Asia Generic Injectable Market Attractiveness Analysis By Application, 2021-2031

Figure 67: East Asia Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021-2031

Figure 68: East Asia Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021-2031

Figure 69: East Asia Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021-2031

Figure 70: Oceania Generic Injectable Market Size Analysis, 2016–2020

Figure 71: Oceania Generic Injectable Market Forecast & Y-o-Y growth, 2021–2031

Figure 72: Oceania Generic Injectable Market Attractiveness Analysis By Country, 2021-2031

Figure 73: Oceania Generic Injectable Market Attractiveness Analysis By Product Type, 2021-2031

Figure 74: Oceania Generic Injectable Market Attractiveness Analysis By Application, 2021-2031

Figure 75: Oceania Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021-2031

Figure 76: Oceania Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021-2031

Figure 77: Oceania Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021-2031

Figure 78: MEA Generic Injectable Market Size Analysis, 2016–2020

Figure 79: MEA Generic Injectable Market Forecast & Y-o-Y growth, 2021–2031

Figure 80: MEA Generic Injectable Market Attractiveness Analysis By Country, 2021-2031

Figure 81: MEA Generic Injectable Market Attractiveness Analysis By Product Type, 2021-2031

Figure 82: MEA Generic Injectable Market Attractiveness Analysis By Application, 2021-2031

Figure 83: MEA Generic Injectable Market Attractiveness Analysis By Molecule Type, 2021-2031

Figure 84: MEA Generic Injectable Market Attractiveness Analysis By Route of Administration, 2021-2031

Figure 85: MEA Generic Injectable Market Attractiveness Analysis By Distribution Channel, 2021-2031

Figure 86: U.S. Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 87: U.S. Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 88: U.S. Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 89: U.S. Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 90: U.S. Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 91: U.S. Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 92: Canada Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 93: Canada Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 94: Canada Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 95: Canada Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 96: Canada Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 97: Canada Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 98: Brazil Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 99: Brazil Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 100: Brazil Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 101: Brazil Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 102: Brazil Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 103: Brazil Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 104: Mexico Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 105: Mexico Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 106: Mexico Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 107: Mexico Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 108: Mexico Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 109: Mexico Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 110: Argentina Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 111: Argentina Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 112: Argentina Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 113: Argentina Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 114: Argentina Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 115: Argentina Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 116: Germany Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 117: Germany Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 118: Germany Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 119: Germany Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 120: Germany Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 121: Germany Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 122: Italy Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 123: Italy Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 124: Italy Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 125: Italy Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 126: Italy Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 127: Italy Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 128: France Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 129: France Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 130: France Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 131: France Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 132: France Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 133: France Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 134: U.K Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 135: U.S. Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 136: U.K Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 137: U.K Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 138: U.K Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 139: U.K Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 140: Spain Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 141: Spain Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 142: Spain Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 143: Spain Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 144: Spain Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 145: Spain Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 146: BENULUX Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 147: BENULUX Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 148: BENULUX Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 149: BENULUX Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 150: BENULUX Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 151: BENULUX Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 152: Russia Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 153: Russia Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 154: Russia Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 155: Russia Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 156: Russia Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 157: Russia Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 158: China Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 159: China Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 160: China Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 161: China Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 162: China Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 163: China Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 164: Japan Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 165: Japan Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 166: Japan Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 167: Japan Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 168: Japan Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 169: Japan Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 170: South Korea Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 171: South Korea Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 172: South Korea Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 173: South Korea Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 174: South Korea Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 175: South Korea Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 176: India Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 177: India Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 178: India Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 179: India Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 180: India Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 181: India Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 182: Thailand Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 183: Thailand Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 184: Thailand Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 185: Thailand Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 186: Thailand Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 187: Thailand Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 188: Malaysia Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 189: Malaysia Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 190: Malaysia Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 191: Malaysia Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 192: Malaysia Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 193: Malaysia Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 194: Australia Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 195: Australia Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 196: Australia Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 197: Australia Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 198: Australia Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 199: Australia Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 200: New Zealand Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 201: New Zealand Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 202: New Zealand Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 203: New Zealand Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 204: New Zealand Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 205: New Zealand Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 206: GCC Countries Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 207: GCC Countries Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 208: GCC Countries Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 209: GCC Countries Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 210: GCC Countries Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 211: GCC Countries Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Figure 212: South Africa Generic Injectable Market  Share Analysis (%), by Product Type, 2021 & 2031

Figure 213: South Africa Generic Injectable Market  Share Analysis (%), by Molecule Type, 2021 & 2031

Figure 214: South Africa Generic Injectable Market  Share Analysis (%), by Application, 2021 & 2031

Figure 215: South Africa Generic Injectable Market  Share Analysis (%), by Route Of Administration, 2021 & 2031

Figure 216: South Africa Generic Injectable Market  Share Analysis (%), by Distribution Channel, 2021 & 2031

Figure 217: South Africa Generic Injectable Market  Value Analysis (US$ Mn), 2021 & 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Generic Injectable Market